Current therapeutic strategies for respiratory diseases using mesenchymal stem cells

• Published in: MedComm (2020) Vol. 2; no. 3; pp. 351 - 380
• Main Authors: Wang, Ming‐yao, Zhou, Ting‐yue, Zhang, Zhi‐dong, Liu, Hao‐yang, Zheng, Zhi‐yao, Xie, Hui‐qi
• Format: Journal Article
• Language: English
• Published: Beijing John Wiley & Sons, Inc 01.09.2021; John Wiley and Sons Inc; Wiley
• Subjects: acute respiratory distress syndrome; Asthma; chronic obstructive pulmonary disease; idiopathic pulmonary fibrosis; mesenchymal stem cells; Pulmonary fibrosis; Respiratory diseases; Review; Reviews; Stem cells
• ISSN: 2688-2663; 2688-2663
• DOI: 10.1002/mco2.74

Mesenchymal stromal/stem cells (MSCs) have a great potential to proliferate, undergo multi‐directional differentiation, and exert immunoregulatory effects. There is already much enthusiasm for their therapeutic potentials for respiratory inflammatory diseases. Although the mechanism of MSCs‐based therapy has been well explored, only a few articles have summarized the key advances in this field. We hereby provide a review over the latest progresses made on the MSCs‐based therapies for four types of inflammatory respiratory diseases, including idiopathic pulmonary fibrosis, acute respiratory distress syndrome, chronic obstructive pulmonary disease, and asthma, and the uncovery of their underlying mechanisms from the perspective of biological characteristics and functions. Furthermore, we have also discussed the advantages and disadvantages of the MSCs‐based therapies and prospects for their optimization. The dominant functions of MSCs in IPF, ARDS, COPD and Asthma.